Gistinfo

Current Research

• GIST Research Update Presentation at 2012 Pittsburgh event.

• Presentation from the University of Oregon Meeting

• The War on GIST: Life, Death, and Everything In Between - GCRF Research Update 2012 (Michael Heinrich, M.D.)

• GIST Research Updates: May 2012, Heinrich & Corless Laboratories 

• GIST Research Update:  Fox Chase Cancer Center (Margaret von Mehren, MD) 

• Oncogenesis of wild type GIST: some clarity from genetics (Fox Chase Cancer Center - Martin G. Belinsky Ph.D. ) 

• Evaluating new therapies in GIST using in vivo molecular imaging (Fox Chase Cancer Center - Lori Rink, Ph.D.)

• Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor Activity
• Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)
• Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST) (PAZOGIST)
• Study of Regorafenib as a 3rd-line or Greater Treatment for Gastrointestinal Stromal Tumors (GIST) (GRID)
• Proapoptotic Activity of Bortezomib in Gastrointestinal Stromal Tumor Cells

• A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)

• Drug shows promise as new treatment for gut tumor

• Synta Presents Preclinical Data on Next Generation Hsp90 Inhibitor, STA-9090

• Analysis of KIT Mutations in Sporadic and Familial Gastrointestinal Stromal Tumors: Therapeutic Implications through Protein Modeling

• Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT

• Insulin-like growth factor binding protein-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to the anti-tumor effects of imatinib mesylate in vitro

• Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT

• Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor

• Informative presentation onImatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors